NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both progression-free survival (PFS) and overall survival (OS) in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). The data, bolstered by a fresh topline report
As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as the pioneer of RNA interference (RNAi) technology, Alnylam has successfully transitioned from a research-heavy enterprise to a fully integrated, profitable commercial leader. With the recent expansion of [...]
As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the Delaware-based biopharmaceutical giant is currently undergoing a radical transformation. Today, the stock is under heavy scrutiny following yesterday’s fiscal year 2025 earnings report. While [...]
Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner, growth-oriented neurology powerhouse. Despite a 7% year-over-year revenue decline to $2.28 billion, the company beat Wall Street expectations
As of February 6, 2026, the global financial landscape is still reverberating from a historic tectonic shift that occurred in the final months of last year. In the fourth quarter of 2025, the M&A market witnessed an unprecedented "mega-deal" frenzy, with 22 global transactions valued at over $10 billion
As of February 6, 2026, Biogen Inc. (NASDAQ: BIIB) stands at a critical crossroads in its nearly 50-year history. Once the undisputed titan of the Multiple Sclerosis (MS) market, the Cambridge-based biotechnology pioneer is now navigating an aggressive and complex transition. Under the leadership of CEO Christopher Viehbacher, Biogen has spent the last two years [...]
Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments.
As of early 2026, the promise of “digital-first” drug discovery has shifted from a speculative horizon to a tangible industrial reality. Since its groundbreaking release in May 2024, AlphaFold 3 (AF3)—the generative AI model developed by Google DeepMind and its commercial sibling, Isomorphic Labs—has fundamentally transformed the landscape of molecular biology. By expanding beyond simple [...]
In a strategic move to solidify its dominance in the burgeoning field of oral anti-inflammatories, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, a definitive agreement to acquire Ventyx Biosciences (NASDAQ:VTYX) for approximately $1.2 billion. The all-cash deal, valued at $14.00 per share, marks
In the annals of scientific history, few moments represent a clearer "before and after" than the arrival of AlphaFold 3. Developed by Google DeepMind and its dedicated drug-discovery arm, Isomorphic Labs, this model has fundamentally shifted the paradigm of biological research. While its predecessor famously solved the 50-year-old protein-folding problem, AlphaFold 3 has gone significantly [...]
In the quest to cure humanity’s most devastating diseases, the bottleneck has long been the "wet lab"—the arduous, years-long process of trial and error required to find a protein that can stick to a target and stop a disease in its tracks. However, a seismic shift occurred with the maturation of AlphaProteo, a generative AI [...]
